111 results about "Mitomycin C" patented technology

A method of preparing and using a sterile non-toxic pyrogen-free cold extract from the leaves of Nerium oleander as a supplementary medication to cancer chemo-, hormon and/or radiotherapy to restore and/or ameliorate the immune system of the patient and/or to decrease side effects and increase the antitumor effects of radiotherapy and chemotherapeutics, particularly when used in combination with taxol, adriamycin, cisplatin, 5-fluoro-uracil, alimta, cyclophosphamide, mitomycin-C, navelbine, taxotere and topotecan, respectively, and its use in the manufacture of a medicament for the treatment of one or more cancers of bladder, kidney, liver, ovary, pancreas, testicle, uterus, and vagina as well as pleuramesotheliomas and Hodgkin's lymphomas.

The invention discloses an inducing method for directionally differentiating human embryonic stem cells to corneal endothelial cells. The method comprises the steps of: cultivating the human embryonic stem cells on a mouse embryonic fibroblast feed layer; sorting human embryonic stem cell clone groups in good state; grafting the groups on a human corneal stromal fibroblast layer processed by mitomycin C and cultivating for 7 days, wherein the human embryonic stem cells are differentiated to rosettes; separating and transferring the rosettes from the human corneal stromal fibroblast layer to a culture bottle; cultivating continuously for 7 days by using a neural crest stem cell culture medium; sorting the neural crest stem cells by a flow cytometry; adding the neural crest stem cells into the culture bottle; placing in a 5% CO2 incubator for incubating and cultivating at 37 DEG C by using a human corneal endothelial cell culture medium; changing the liquid every other day; and cultivating for about 10 days to obtain the corneal endothelial cells. The multiplication capacity of the corneal endothelial cells are similar to that of human corneal endothelial cells and the corneal endothelial cells can be transferred to 1-2 generations in vitro maximally. The corneal endothelial cells can be used as seed cells for cornea construction and transplant in tissue engineering.

The present invention provides a new type balloon dilation catheter which includes ballon and medication material coated on stent. Said medication material comes from one or two and more than two mixtures of heparin sodium, fiber degrading enzyme, serine proteinase, batroxobin, aspirin, genistein, hirudin and its recombined product, colchicine, sirolimus, biolimus, zotarolimus, tracrolimus, pimecrolimus, simvastatin, atorvastatin, pravastatin, ciclosporin, Anti-CD34, dexamethasone, bleomycin, plicamycin, daunomycin, mitomycin C, actinomycin D, taxol, celastrol, methopterin, 5-fluorouracil, cytarabine and 6-purinethol. The balloon is made of macromolecule nylon material, and the stimulation to blood vessel is far lower than the stent with metal structure.

The invention discloses a human umbilical cord blood hematopoietic stem cell (HSC) high-efficiency in vitro amplification technology. According to the invention, umbilical cord mesenchymal stem cells (MSCs) and umbilical cord blood plasma are used in combination for carrying out HSC in vitro amplification. A process comprises steps that: umbilical cord MSCs are cultured as a trophoblast; a special culture solution containing umbilical cord blood plasma is adopted as an amplification medium of the HSCs; and umbilical cord blood karyotes are adopted as amplification initiator cells. According to the invention, exogenous cell factors are not required to be added, treatments such as mitomycin C or gamma-ray 21Gy irradiation are not required by the trophoblast, no 3-dimensional technology is required, and the HSC high-efficiency amplification can be carried out. The technology is advantaged in low cost, convenient amplification, and low product immunogenicity. The technology is suitable for large-scaled productions. The practical application of the technology plays an important role in clinical treatments and researches.

An apparatus for preparing a pharmaceutical for transient application includes a tray having a sealed compartment, a vial of an ophthalmic formulation of mitomycin-C, a diluent carrier containing sterilized water, and a syringe that are all contained together in a single package. The component parts of the apparatus are used together to reconstitute the contents of the vial with the water in the diluent carrier, and then draw the reconstituted drug into the sealed compartment of the tray by a suction force produced by the syringe. In the tray compartment, the reconstituted drug is absorbed in an absorbent pad. The tray is opened to remove the pad and the absorbed drug from the tray compartment for use of the pad in transient application of the drug.

The invention discloses a mouse fibroblast and an application thereof, and belongs to the field of cell biology. The cell is named mouse fibroblast MFC/HL-041 with the preservation number of CCTCC NO:C201714. The mouse fibroblast treated by mitomycin C or irradiated by radioactive rays is used for separation and subculture of normal primary epithelial cells and primary tumor cells. Obtained humanpulmonary normal primary epithelial cells and lung cancer primary epithelial cells are fresh and live in state, tight in arrangement, clear in cell boundary, high in stereoscopic impression and polygonal when examined under a microscope. The mouse fibroblast can be used for physiological study of human or animal normal cells, a virus infection model of in-vitro normal cells, drug sensitivity tests of the in-vitro normal cells for different drugs, drug screening for individualized treatment of cancer patients as well as research and development of new anti-cancer drugs.

The invention discloses a method of utilizing human umbilical cord mesenchymal stem cells as a feed layer to culture human induced pluripotent stem cells. The method comprises the following steps: (1) preparation of the feed layer: taking the human umbilical cord mesenchymal stem cells, inoculating the cells to a culture dish until the cell confluence degree is 40-60%, adding 5-15 ug/ml of mitomycin C, processing the culture for 2-4 h, removing mitomycin C, and obtaining the feed layer; (2) culture: inoculating the human induced pluripotent stem cells to the feed layer which is prepared in the step (1), culturing, and finishing. The method can be used for effectively culturing the human induced pluripotent stem cells for a long time, is free from pollution of heterogonous cells and heterogonous proteins, and has good application prospect.

Anthracyclin-treated turn or cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclins induce the rapid, pre-apoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knock down of CRT suppressed the phagocytosis of anthracyclin-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. The anthracyclin-induced CRT translocation was mimicked by inhibition of the protein phosphatase1/GADD34 complex. Administration of recombinant CRT or inhibitors of protein phosphatase1/GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo. These data identify CRT as a key feature determining anti-cancer immune responses and delineate a possible strategy for immunogenic chemotherapy.

The invention relates to anticancer sustained release injection which comprises sustained release microspheres and menstruum, wherein, the sustained release microspheres comprise anticancer active components and sustained release auxiliary material; the menstruum is special menstruum that contains suspending agent. The anticancer active components are fotemustine, nimustine, carmustine or combination of bendamustine and mitozolomide, docetaxel, etoposide, teniposide, vinblastine, anastrozole, tamoxifen, fluorouracil or mitomycin C; the sustained release auxiliary material is polylactic acid and polylactic acid copolymer, polyethylene glycol and polylactic acid copolymer of polyethylene glycol, terminal carboxyl group polylactic acid copolymer, EVAc, fatty acid and decanedioic acid copolymer, etc.; viscosity of the suspending agent is 100cp-3,000cp (at 25 DEG C-30 DEG C), and the suspending agent is selected from sodium carboxymethylcellulose, etc. The sustained release microspheres can also be made into sustained release implant; the injection or implant is injected or placed in or around tumor so as to reduce general reaction of the drug and selectively improve and keep local concentration for about 30-50 days. The anticancer sustained release injection can be used solely and can also promote anti-tumor effects of non-operative treatments, such as chemotherapy and/or radiotherapy, etc.

The invention discloses a method for developing and cultivating human induced pluripotent stem cells. The method is characterized by comprising the steps of a, preparing a human fibroblast-like cell feeding layer, seeding human fibroblast-like cells onto a petri dish, and processing 10mg/ml mitomycin C for three hours in advance to remove mitomycin C; b, reprogramming somatic cells, generating the human induced pluripotent stem cells, and transplanting the human induced pluripotent stem cells into the feeding layer prepared in the step a to be cultivated. By the adoption of the technical scheme, the influence of heterologous cells and heterologous protein on the induced pluripotent stem cells is avoided, transcription efficiency is high, the differentiation capacity of the induced pluripotent stem cells is not affected, the number of cultivation generations is large, life is long, and the method has huge potential clinically.

The invention belongs to the field of stem cell culture, and particularly relates to a cell culture medium and a stem cell culture method. The invention provides a stem cell culture medium. The stem cell culture medium comprises a basic culture medium, a platelet lysate, an L-Glutamine and a mitomycin c. The invention also provides a stem cell separating method. The stem cell separating method comprises the following steps that the in-vitro tissue and the stem cell culture medium are mixed to be placed in a culture flask for culturing until cells creep out from the in-vitro tissue, the in-vitro tissue is scraped; the culture of the cells is continued, when the fusion degree of stem cells in the culture flask reaches 80% to 90%, the cells are passage-cultured after digestion. The stem cell culture medium can avoid the risk that the existing stem cell culture medium contains mostly animal serum so as to introduce exogenous virus; the stem cell separating method is simple to operate.

The invention relates to an application of salvianolic acid L in preparation of medicines used for treating tumor, salvianolic acid L belongs to a phenolic acid compound which is a novel water-soluble compound with a confirmed structure extracted from a traditional Chinese medicine red sage root, a pharmacological research shows that the phenolic acid possesses anti-oxidation effect and anti-myocardial ischemia effect. According to the invention, the salvianolic acid L induces the apoptosis of tumor cells and also can kill the tumor cells. Animal experiments show that salvianolic acid L possesses certain antineoplastic activity and does not appear toxicity, and is capable of substantially enhancing antineoplastic activity of various tumor medicines 5-fluorouracil, mitomycin C and the like, the compound is expected to be used for clinical tumor treatment.

The invention provides a preparation method for improving productivity of mitomycin C. The preparation method comprises the following steps: adding a composite precursor containing citrulline and arginine and HP-21 resin into a fermentation medium of the mitomycin C to prepare a dedicated fermentation medium; and culturing the head-shaped streptomyces generating mitomycin C respectively through a slant medium and a seed medium, then transferring to the prepared dedicated fermentation medium for culturing. Due to the action of the composite precursor containing citrulline and arginine, the content of mitomycin C in the effective compound generated by fermentation is greatly improved to 30-45 percent, so that the production cost of mitomycin C can be greatly reduced, as a result, the method for preparing mitomycin C has favorable industrial prospect.

The present invention features monoclonal antibodies LA1 or LA22 conjugated with mitomycin C, pingyangmycin or other anti-cellular agents. The present invention also features other anti-EGFR antibodies conjugated with mitomycin C or pingyangmycin. The antibodies of the present invention can be used to treat cancers, including but not limited to, those of epithelial origin, such as glioblastoma or cancer of the lung, breast, head and neck, and bladder.

The invention belongs to the technical field of microbes and specifically relates to Stenotrophomonas maltophilia and wide-spectrum maltocin synthesized from Stenotrophomonas maltophilia and application thereof. The Stenotrophomonas maltophilia is named Stenotrophomonas maltophilia S16 strain and was preserved in the China Center for Type Culture Collection with the preservation number being CCTCCM 2017431. The Stenotrophomonas maltophilia S16 strain is a new strain, and the strain can be induced by mitomycin C to produce maltocin S16. The maltocin S16 has high bactericidal activity and widebactericidal spectrum, can kill most Stenotrophomonas maltophilia as well as Escherichia coli, has resistance to protease, is relatively stable at high temperature, and has a good development and application prospect.

The invention relates to the field of medical anti-tumor drug preparations, in particular to a tumor targeted mitomycin C and MTX (methotrexate) double-drug preparation for preventing malignant tumor growth and recurrence and a preparation method of the double-drug preparation. The tumor targeted mitomycin C and MTX double-drug preparation comprises a crude drug of mitomycin C, a carrier material and an MTX prodrug with targeting and anti-cancer functions, wherein the carrier material adopts lecithin and DSPE-PEG (distearoyl phosphoethanolamine-polyethylene glycol), and the MTX prodrug adopts DSPE-PEG-MTX. The tumor targeted mitomycin C and MTX double-drug preparation is spherical, has the grain diameter distributed between 20 nm and 80 nm, is suitable for being used as an intravenous injection preparation and has the characteristics of high targeting, long circulation, low toxicity and collaborative treatment.